EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji, +19

Nature

Ezh2 InhibitionLymphoid NeoplasiaHematological MalignancyMedicinePathology +8

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li, +31

Cell

Kras Mutant CancersMedicineAnti-cancer AgentCancer BiologyRadiation Oncology +4

ATP citrate lyase inhibition can suppress tumor cell growth

Georgia Hatzivassiliou, Fangping Zhao, Daniel E. Bauer, +6

Cancer Cell

Tumor Cell GrowthMedicineTumor SuppressorCellular BiochemistryCancer Biology +3

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin, +51

Nature Chemical Biology

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat, +30

Cancer Cell

Oncogenic AgentMedicineEpigenetic ChangePharmacologyLsd1 Inhibitors +7

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

Paweł K. Mazur, Nicolas Reynoird, Purvesh Khatri, +14

Nature

Lysine MethylationMedicineCancer GenomicsCancer GeneticsCancer Biology +3

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma, Xinrong Tian, Louis V. LaFrance, +24

ACS Medicinal Chemistry Letters

Histone ModificationsDrug Discovery ProgramEngineeringEpigenetic ChangeCell-active Inhibitors +16

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess, +28

ACS Medicinal Chemistry Letters

Highly Potent InhibitorTumor BiologyMammalian TargetSignaling PathwayCancer Cell Biology +14

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo, +32

Proceedings of the National Academy of Sciences

Antitumor ActivityCenp-e Motor ActivityMolecular BiologyCell DeathCytoskeleton +16

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

Anastasia Wyce, Gopinath Ganji, Kimberly N. Smitheman, +16

PLoS ONE

Mycn Copy NumberBet Family ProteinsCell RegulationOncogenic AgentMedicine +12